Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-BLADDER
NCT03317158Phase 2Active, not recruiting
- Start
- Nov 2017
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, nogapendekin alfa inbakicept in non-muscle-invasive bladder cancer (NMIBC). Started Nov 2017; status: active, not recruiting.
02
Drugs
durvalumabnogapendekin alfa inbakicept
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03317158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317158.